

Special Issue

Precision Medicine for Neuroblastoma

Message from the Guest Editors

Cancer often is called the poster child of personalized medicine. Thus, it is timely to look at the impact that new molecular insights have had on childhood cancers. This Special Issue of the *Journal of Personalized Medicine* discusses progress that has been made in neuroblastoma, which is one of the most frequent solid tumours in children and hallmarked by its extreme heterogeneity. Papers in this Special Issue review scientific advances that have improved patient stratification and treatment choices, the introduction of new targeted treatments and immunotherapies in the clinic, new strategies to deal with drug resistance and relapsed disease, and emerging areas, such as the role of tumor metabolism and the tumor microenvironment. Our aim is to provide an overview that includes both scientific and clinical advances on the road to the personalized diagnosis and treatment of neuroblastoma.

Guest Editors

Prof. Dr. Walter Kolch


Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland

Dr. Cormac Owens

Our Lady's Children's Hospital, Crumlin, Cooley Road, Crumlin Dublin 12, Ireland

Deadline for manuscript submissions

closed (25 September 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/53607

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).